<p>，/PRNewswire/ -- Pomerantz LLP 宣布已对 Immutep Limited（&#34;Immutep&#34; 或 &#34;公司&#34;）（NASDAQ: IMMP）提起集体诉讼。建议相关投资者联系 Danielle Peyton，邮箱为 [email protected] 或拨打 646-581-9980（或 888.4-POMLAW），免费电话，分机 7980。通过电子邮件咨询的人员被鼓励提供他们的邮寄地址、电话号码和购买的股票数量。</p>
<p>该集体诉讼涉及 Immutep 及其某些高管和/或董事是否参与了证券欺诈或其他非法商业行为。</p>
<p><strong>如果您在集体诉讼期间购买或以其他方式获得了</strong> <strong>Immutep</strong> <strong>证券，您有时间在 2026 年 7 月 6 日之前请求法院任命您为集体的首席原告。投诉的副本可以在</strong> <strong>www.pomerantzlaw.com</strong> <strong>获取。</strong></p>
<p><strong>[点击此处获取有关加入集体诉讼的信息]</strong></p>
<p>2026 年 3 月 13 日，Immutep 发布了一份新闻稿，&#34;宣布独立数据监测委员会（IDMC）对评估 eftilagimod alfa（'efti'）在一线非小细胞肺癌患者中的 TACTI-004 III 期研究的建议，在根据研究协议进行的计划中期无效性分析后，建议停止该试验。&#34; 根据新闻稿，&#34;[b] 根据对可用安全性和有效性数据的审查，IDMC 建议因无效性停止该试验&#34;，因此，&#34;研究的招募将被暂停，公司将按照监管和伦理义务有序结束研究，包括适当的患者跟进和现场关闭。&#34;</p>
<p>在这一消息发布后，Immutep 的美国存托凭证（&#34;ADR&#34;）价格下跌 2.27 美元，或 82.44%，于 2026 年 3 月 13 日收于每个 ADR 0.48 美元。</p>
<p>Pomerantz LLP 在纽约、芝加哥、洛杉矶、伦敦、巴黎和特拉维夫设有办事处，被公认为公司、证券和反垄断集体诉讼领域的顶尖律所之一。该公司由已故的 Abraham L. Pomerantz 创立，他被称为集体诉讼领域的权威，Pomerantz 在证券集体诉讼领域开创了先河。今天，85 年后，Pomerantz 继续秉承他所建立的传统，为证券欺诈、违反信托责任和公司不当行为的受害者争取权利。该公司已为集体成员追回了数百万美元的赔偿。请参见 www.pomlaw.com。</p>
<p>律师广告。以前的结果并不保证类似的结果。</p>
<p><strong>联系方式：</strong></p>
<p>Danielle Peyton</p>
<p>Pomerantz LLP</p>
<p>[email protected]</p>
<p>646-581-9980 分机 7980</p>
<p>来源 Pomerantz LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REM2MDQzMSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQyMDAyUFJfTkVXU19VU1BSX19fX19EQzYwNDMx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REM2MDQzMSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQyMDAyUFJfTkVXU19VU1BSX19fX19EQzYwNDMx"/></p>

IMMP

<p>Pomerantz 律师事务所已对 Immutep Limited（NASDAQ: IMMP）提起集体诉讼，指控其涉嫌证券欺诈。遭受损失的投资者被鼓励在 2026 年 7 月 6 日之前联系该事务所，以被任命为首席原告。该诉讼是在 Immutep 的股价大幅下跌后提起的，此前独立数据监测委员会建议因无效性停止一项 III 期研究。Pomerantz LLP 专注于公司和证券集体诉讼，致力于为公司不当行为的受害者辩护</p>

<p>, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited (&#34;Immutep&#34; or the &#34;Company&#34;) (NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- Pomerantz LLP 宣布已对 Immutep Limited（&#34;Immutep&#34; 或 &#34;公司&#34;）（NASDAQ: IMMP）提起集体诉讼。建议相关投资者联系 Danielle Peyton，邮箱为 [email protected] 或拨打 646-581-9980（或 888.4-POMLAW），免费电话，分机 7980。通过电子邮件咨询的人员被鼓励提供他们的邮寄地址、电话号码和购买的股票数量。</p>
</div><p>The class action concerns whether Immutep and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.</p>
<div class="lb-trans"><p>该集体诉讼涉及 Immutep 及其某些高管和/或董事是否参与了证券欺诈或其他非法商业行为。</p>
</div><p><strong>You have July 6, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired</strong> <strong>Immutep</strong> <strong>securities during the Class Period. A copy of the Complaint can be obtained at</strong> <strong>www.pomerantzlaw.com</strong> <strong>.</strong></p>
<div class="lb-trans"><p><strong>如果您在集体诉讼期间购买或以其他方式获得了</strong> <strong>Immutep</strong> <strong>证券，您有时间在 2026 年 7 月 6 日之前请求法院任命您为集体的首席原告。投诉的副本可以在</strong> <strong>www.pomerantzlaw.com</strong> <strong>获取。</strong></p>
</div><p><strong>[Click here for information about joining the class action]</strong></p>
<div class="lb-trans"><p><strong>[点击此处获取有关加入集体诉讼的信息]</strong></p>
</div><p>On March 13, 2026, Immutep issued a press release &#34;announc[ing] that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol.&#34; According to the press release, &#34;[b] ased on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility&#34; and that, accordingly, &#34;enrolment in the study will be halted and the Company will implement an orderly wind down of the study, including appropriate patient follow up and site close out in accordance with regulatory and ethical obligations.&#34;</p>
<div class="lb-trans"><p>2026 年 3 月 13 日，Immutep 发布了一份新闻稿，&#34;宣布独立数据监测委员会（IDMC）对评估 eftilagimod alfa（'efti'）在一线非小细胞肺癌患者中的 TACTI-004 III 期研究的建议，在根据研究协议进行的计划中期无效性分析后，建议停止该试验。&#34; 根据新闻稿，&#34;[b] 根据对可用安全性和有效性数据的审查，IDMC 建议因无效性停止该试验&#34;，因此，&#34;研究的招募将被暂停，公司将按照监管和伦理义务有序结束研究，包括适当的患者跟进和现场关闭。&#34;</p>
</div><p>On this news, Immutep's American Depositary Receipt (&#34;ADR&#34;) price fell $2.27 per ADR, or 82.44%, to close at $0.48 per ADR on March 13, 2026.</p>
<div class="lb-trans"><p>在这一消息发布后，Immutep 的美国存托凭证（&#34;ADR&#34;）价格下跌 2.27 美元，或 82.44%，于 2026 年 3 月 13 日收于每个 ADR 0.48 美元。</p>
</div><p>Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.</p>
<div class="lb-trans"><p>Pomerantz LLP 在纽约、芝加哥、洛杉矶、伦敦、巴黎和特拉维夫设有办事处，被公认为公司、证券和反垄断集体诉讼领域的顶尖律所之一。该公司由已故的 Abraham L. Pomerantz 创立，他被称为集体诉讼领域的权威，Pomerantz 在证券集体诉讼领域开创了先河。今天，85 年后，Pomerantz 继续秉承他所建立的传统，为证券欺诈、违反信托责任和公司不当行为的受害者争取权利。该公司已为集体成员追回了数百万美元的赔偿。请参见 www.pomlaw.com。</p>
</div><p>Attorney advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p>律师广告。以前的结果并不保证类似的结果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Danielle Peyton</p>
<div class="lb-trans"><p>Danielle Peyton</p>
</div><p>Pomerantz LLP</p>
<div class="lb-trans"><p>Pomerantz LLP</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>646-581-9980 ext. 7980</p>
<div class="lb-trans"><p>646-581-9980 分机 7980</p>
</div><p>SOURCE Pomerantz LLP</p>
<div class="lb-trans"><p>来源 Pomerantz LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REM2MDQzMSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQyMDAyUFJfTkVXU19VU1BSX19fX19EQzYwNDMx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC60431&amp;Transmission_Id=202605142002PR_NEWS_USPR_____DC60431&amp;DateId=20260514"/></p>

20:02 ETINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

投资者警示：Pomerantz 律师事务所提醒在 Immutep Limited 投资中遭受损失的投资者注意集体诉讼及即将到来的截止日期 - IMMP